By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

4SC AG 

Am Klopferspitz 19a

Martinsried    82152  Germany
Phone: 49-0-89-7007630 Fax: 49-0-89-700763-29


SEARCH JOBS


Industry
Biotechnology






Company News
4SC AG (VSC.F) in Talks With 3 Potential Partners for Cancer Drug 9/13/2012 8:00:37 AM
4SC AG (VSC.F) Says Its Resminostat Meets Primary Endpoint In Phase II Trial 1/19/2012 11:00:19 AM
4SC AG (VSC.F)'s Anti-Cancer Compound Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation in Europe to Treat Hodgkin's Lymphoma 10/13/2011 10:21:46 AM
4SC AG (VSC.F)'s Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma 9/26/2011 9:36:52 AM
4SC AG (VSC.F)'s Resminostat Meets Primary Efficacy Endpoint in Phase II Trial in Hodgkin's Lymphoma (HL) 9/6/2011 6:46:24 AM
FDA Grants Orphan Drug Designation to 4SC AG (VSC.DU)'s Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma 7/12/2011 9:47:27 AM
4SC AG (VSC.DU) Says Vidofludimus Trial Missed Primary Efficacy Endpoint In RA 6/10/2011 7:12:13 AM
4SC AG (VSC.DU): Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model 5/27/2011 11:05:16 AM
Arthritis Drug's $1.4 Billion Promise for German Drugmaker 4SC AG (VSC.DU) Hinges on Study, Could Present Itself as Pfizer Inc. (PFE)'s Main Oral RA Competition 5/27/2011 7:23:12 AM
4SC AG (VSC.DU) Presents Final Phase IIa Data on Vidofludimus in Inflammatory Bowel Disease Study at the 6th ECCO IBD Conference 2/28/2011 9:06:59 AM
1234
//-->